Saphris: Does a unique delivery system equal a unique drug?

Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative propert...

Full description

Saved in:
Bibliographic Details
Published in:The mental health clinician 2011-12, Vol.1 (6), p.133-134
Main Author: Gable, Kelly N.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 134
container_issue 6
container_start_page 133
container_title The mental health clinician
container_volume 1
creator Gable, Kelly N.
description Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.
doi_str_mv 10.9740/mhc.n89388
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_9740_mhc_n89388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_9740_mhc_n89388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1418-c0ab19f04a551d881f3a8f7533d162def2a13fb077e2e2a4e1c2baed2dc20d083</originalsourceid><addsrcrecordid>eNpNz0tLAzEUBeAgCpbajb8ga2Hqvck8El2I1CcUXKjr4U5yY0dm-kgcYf69Sl10dQ4cOPAJcY4wt1UOl_3KzdfGamOOxERhaTJbgT0-6KdiltInACjAvCjtRFy_0nYV23Ql7zacJMlh3e4Glp679pvjKNOYvriXvBuoO5jj8HFzJk4CdYln_zkV7w_3b4unbPny-Ly4XWYOczSZA2rQBsipKNAbg0GTCVWhtcdSeQ6KUIcGqooVK8oZnWqIvfJOgQejp-Ji_-viJqXIod7Gtqc41gj1n7z-ldd7uf4BMe1L9A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Saphris: Does a unique delivery system equal a unique drug?</title><source>EZB Free E-Journals</source><creator>Gable, Kelly N.</creator><creatorcontrib>Gable, Kelly N.</creatorcontrib><description>Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.</description><identifier>ISSN: 2168-9709</identifier><identifier>EISSN: 2168-9709</identifier><identifier>DOI: 10.9740/mhc.n89388</identifier><language>eng</language><ispartof>The mental health clinician, 2011-12, Vol.1 (6), p.133-134</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Gable, Kelly N.</creatorcontrib><title>Saphris: Does a unique delivery system equal a unique drug?</title><title>The mental health clinician</title><description>Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.</description><issn>2168-9709</issn><issn>2168-9709</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNpNz0tLAzEUBeAgCpbajb8ga2Hqvck8El2I1CcUXKjr4U5yY0dm-kgcYf69Sl10dQ4cOPAJcY4wt1UOl_3KzdfGamOOxERhaTJbgT0-6KdiltInACjAvCjtRFy_0nYV23Ql7zacJMlh3e4Glp679pvjKNOYvriXvBuoO5jj8HFzJk4CdYln_zkV7w_3b4unbPny-Ly4XWYOczSZA2rQBsipKNAbg0GTCVWhtcdSeQ6KUIcGqooVK8oZnWqIvfJOgQejp-Ji_-viJqXIod7Gtqc41gj1n7z-ldd7uf4BMe1L9A</recordid><startdate>201112</startdate><enddate>201112</enddate><creator>Gable, Kelly N.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201112</creationdate><title>Saphris: Does a unique delivery system equal a unique drug?</title><author>Gable, Kelly N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1418-c0ab19f04a551d881f3a8f7533d162def2a13fb077e2e2a4e1c2baed2dc20d083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gable, Kelly N.</creatorcontrib><collection>CrossRef</collection><jtitle>The mental health clinician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gable, Kelly N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Saphris: Does a unique delivery system equal a unique drug?</atitle><jtitle>The mental health clinician</jtitle><date>2011-12</date><risdate>2011</risdate><volume>1</volume><issue>6</issue><spage>133</spage><epage>134</epage><pages>133-134</pages><issn>2168-9709</issn><eissn>2168-9709</eissn><abstract>Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.</abstract><doi>10.9740/mhc.n89388</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-9709
ispartof The mental health clinician, 2011-12, Vol.1 (6), p.133-134
issn 2168-9709
2168-9709
language eng
recordid cdi_crossref_primary_10_9740_mhc_n89388
source EZB Free E-Journals
title Saphris: Does a unique delivery system equal a unique drug?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A02%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Saphris:%20Does%20a%20unique%20delivery%20system%20equal%20a%20unique%20drug?&rft.jtitle=The%20mental%20health%20clinician&rft.au=Gable,%20Kelly%20N.&rft.date=2011-12&rft.volume=1&rft.issue=6&rft.spage=133&rft.epage=134&rft.pages=133-134&rft.issn=2168-9709&rft.eissn=2168-9709&rft_id=info:doi/10.9740/mhc.n89388&rft_dat=%3Ccrossref%3E10_9740_mhc_n89388%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1418-c0ab19f04a551d881f3a8f7533d162def2a13fb077e2e2a4e1c2baed2dc20d083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true